Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during the emergence of Omicron variants BA. 2/BA2. 12.1
NR Aggarwal, KC Molina, LE Beaty, TD Bennett… - Medrxiv, 2022 - medrxiv.org
ABSTRACT Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
[PDF][PDF] Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA. 2/BA2. 12.1
NR Aggarwal - scholar.archive.org
ABSTRACT Background: Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA. 2/BA2. 12.1
NR Aggarwal, KC Molina, LE Beaty, TD Bennett… - 2022 - europepmc.org
Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in vitro activity
against SARS-CoV-2, has been shown to reduce risk of progression to severe COVID-19 …
against SARS-CoV-2, has been shown to reduce risk of progression to severe COVID-19 …